China Proposes Rolling Submissions For Innovative New Drugs
Also Priority Reviews For Breakthrough Products
Executive Summary
A revised regulatory approach in China will include rolling data submissions among new incentives for the development of innovative new drugs in a bid to further accelerate the approval of such products.